(DAYR-uh-TOOM-yoo-mab … HY-al-yoo-RAH-nih-days)
This page contains brief information about daratumumab and hyaluronidase-fihj and a collection of links to more information about the use of this drug, research results, and ongoing clinical trials.
FDA label information for this drug is available at DailyMed.
Use in Cancer
Daratumumab and hyaluronidase-fihj is approved to be used alone or with other drugs to treat:
- Light-chain amyloidosis that is newly diagnosed. It is used with bortezomib, cyclophosphamide, and dexamethasone in adults.¹
- Multiple myeloma in adults with:
- Newly diagnosed disease. It is used:
- With bortezomib, melphalan, and prednisone or with lenalidomide and dexamethasone in patients who cannot receive an autologous stem cell transplant.
- With bortezomib, thalidomide, and dexamethasone in patients who can receive an autologous stem cell transplant.
- Relapsed or refractory disease. It is used:
- With dexamethasone and either lenalidomide or bortezomib in patients who have received at least one therapy.
- Alone in patients who have already received at least three types of therapy that included a proteasome inhibitor and an immunomodulating agent or whose disease is refractory to both a proteasome inhibitor and an immunomodulatory agent.
- With pomalidomide and dexamethasone in patients who have received at least one therapy that included lenalidomide and a proteasome inhibitor.
- With carfilzomib and dexamethasone in patients who have received one to three types of therapy.
- Newly diagnosed disease. It is used:
¹This use is approved under FDA’s Accelerated Approval Program. As a condition of approval, confirmatory trial(s) must show that daratumumab and hyaluronidase-fihj provides a clinical benefit in these patients.
Daratumumab and hyaluronidase-fihj is a form of daratumumab that is given as a subcutaneous injection. This form can be given in less time than daratumumab, which is given as an infusion. For more information about daratumumab that may apply to daratumumab and hyaluronidase-fihj, see the Drug Information Summary for Daratumumab.
Daratumumab and hyaluronidase-fihj is also being studied in the treatment of other types of cancer.
More About Daratumumab and Hyaluronidase-fihj
Definition from the NCI Drug Dictionary – Detailed scientific definition and other names for this drug.
More About Daratumumab and Hyaluronidase-fihj – A lay language summary of important information about this drug that may include the following:
- warnings about this drug,
- what this drug is used for and how it is used,
- what you should tell your doctor before using this drug,
- what you should know about this drug before using it,
- other drugs that may interact with this drug, and
- possible side effects.
Drugs are often studied to find out if they can help treat or prevent conditions other than the ones they are approved for. This patient information sheet applies only to approved uses of the drug. However, much of the information may also apply to unapproved uses that are being studied.
Research Results and Related Resources
Clinical Trials Accepting Patients
Find Clinical Trials for Daratumumab And Hyaluronidase-fihj – Check for trials from NCI’s list of cancer clinical trials now accepting patients.
